

Indian Journal of Chemistry Vol. 61, July 2022, pp. 703-716



Synthesis, characterization and antioxidant activities of novel *N*-substituted pyrazoline derivatives bearing 3-benzo[b]thiophene and 5-styryl substituents

Radhakrishnan Krishnan*^a, Karthik Manikandan Pandy^b, Senthil Kumar Paratharaj^b& Uttam Kumar Ray^b

^a Saraswathi Narayanan College of Arts and Science, Madurai Kamaraj University, Madurai 625 022, Tamil Nadu, India

^b Solara Active Pharma Sciences Limited, R&D Centre, No. 27, Melakottaiyur (PO), Chennai 600 100, Tamil Nadu, India

E-mail: prskradha61@gmail.com

Received 28 September 2021; accepted (revised) 11 February 2022

The new series of N-substituted pyrazoline derivatives bearing benzo[b]thiophene and styryl with trifluoromethyl substitution at *para-* and *meta-* positions were synthesized. The structures of newly synthesized compounds were characterized by UV, IR, NMR, Mass and single crystal XRD (SCXRD) and had been screened for antioxidant activity. The *in vitro* antioxidant activities screening revealed that hydroxyl radical scavenging (HRS) activities of compounds **3c**, **3f**, **4a**, **4e**, **4f**, **5c**, **5d 5e** and **5g** are stronger than the other compounds and the compound **5g** shows much better antioxidant activity.

Keywords: Pyrazoline, benzo[b]thiophene, N-substituted pyrazolines, antioxidant activity, trifluoromethyl cinnamaldehyde

Pyrazolines are considered to be a top-notch scaffold in medicinal chemistry as their derivatives and their hybrid structures exhibit diverse biological activities like anti-bacterial¹, antifungal¹, anti-viral², antitubercular³, anti-inflammatory⁴, anti-cancer^{3,5}, antioxidant⁶, immunosuppressive⁷, analgesic⁸, antidiuretic⁹, anti-helmentic⁹, fungicidal⁹, neuropsychiatric and neurodegenerative disorders⁹ and also used as brightening agents in synthetic fibres¹⁰, fluorescent probes in chemo-sensors¹¹, recognition of transitionsmetal ions¹², electrophotography and electroluminescence¹³. Some of the pyrazoline derivatives with various substituents attached to the N1 nitrogen atom was found to have displayed significant changes in the photo-physical properties of the compounds¹⁴. Moreover. the incorporation of electron donors/acceptors into the molecule of interest gives fine tuning of the physico-chemical properties for enhanced applications in various fields¹⁵. Benzo[b]thiophene is also received a huge attention in medicinal chemistry. Numerous benzo[b]thiophene based compounds are available to treat various types of

diseases¹⁷. The fluorine substitution on organic compounds are now a days widely used strategy in medicinal and applied chemistries as it shows dramatic effects on metabolic stability and physico-chemical properties of the compounds and among the fluorine substitutions, trifluoromethyl substitution will enhance the bioavailability and lipophilicity of the compounds¹⁶. Having said the importance, enhanced properties and applications of the aforementioned moieties we were attracted to design a new molecular entity bearing all the moieties together and able to synthesize a series of N-substituted-2-pyrazoline derivatives bearing styryl¹⁸ with trifluoromethyl substitution and benzo[b]thiophene motifs and studied for their antioxidant activities.

Results and Discussion

Chemistry

The designed 5-styryl substituted pyrazolines were synthesized by the reaction of cinnamyl chalcones with hydrazine in ethanol under reflux condition, and the cinnamyl chalcones in turn were obtained from cinnamaldehyde and 1-(benzo[b]thiophene-2yl)ethan-1-one. In some methods, hydrazones are formed as intermediate which can subsequently cyclized to 2-pyrazolines in the presence of suitable cyclizing agents¹⁹. Generally, the *N*-substituted pyrazolines were synthesized by direct cyclization of chalcones with substituted hydrazines²⁰, and acylation

List of abbreviations: SCXRD: Single crystal X-ray diffractometer; HRS: Hydroxyl radical scavenging; CCDC: Cambridge Crystallographic Data Centre; RNS: Reactive nitrogen species; ROS: Reactive oxygen species; DPPH: 2,2-diphenyl-1-picrylhydrazyl; ABTS: 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid; TMS: Trimethylsilane; TLC: Thin layer chromatography.

using acetic $acid^{21}$, anhydrides²² and acylchlorides with unsubstituted pyrazolines in presence of a suitable base²³. The synthesis of pyrazoline derivatives **3-5(a-g)** was carried out according to the steps shown in reaction Scheme I.

In the initial step, compound 1(a-c) was synthesized via the base-catalysed Claisen-Schmidt condensation of 1-(benzo[b]thiophene-2-yl)ethan-1one with cinnamaldehvde and trifluoromethyl substituted cinnamaldehydes at para- and metapositions. The structure of the compounds 1 (a-c) was confirmed from its spectral data. The IR spectrum showed absorption band at 1638-1640 cm⁻¹ corresponds to C=O stretching frequency, the band at 1595-1577 cm⁻¹ corresponds to conjugated -C=C stretching. ¹³C NMR double bonds spectrum compounds having signal at δ 178.72-183.29 assigned for C=O group conjugated with double bonds.

The compounds 1(a-c) were further treated with hydrazine hydrate in ethanol under reflux condition, which led to the formation of compounds 2(a-c). In the ¹H NMR of compound 2 (a-c), -NH proton appears around at δ 5.8, the CH₂ protons of pyrazoline ring appears as a pair of doublets around at δ 3.4-3.3 and 3.0-2.9. The CH (H_X) proton appeared as a doublet of doublets around at δ 4.6– 4.5 (H_X) due to the vicinal coupling with two magnetically non-equivalent protons of the methylene group at C4 of the pyrazoline ring (H_A and H_B) (²J_{AB} = 15.9 Hz, ³J_{AX} = 9.9 Hz, ³J_{BX} = 8.4 Hz). In the ¹³C NMR of compound **2(a-c)**, the chemical shift values appeared around 59.1 to 63.64 and 34.60 to 39.51 correspond to the pyrazoline ring of CH and CH₂ respectively. Aromatic and other carbon atoms were observed at expected chemical shifts range (Figure 1).

In the third step, compounds 2(a-c) was treated with various *p*-substituted benzoyl chlorides in the presence of triethylamine in dichloromethane solvent,



Figure 1 — Pyrazoline ring structure of compounds 3-5(a-g)



5(a-g): R₁ = H; R₂ = CF₃; R₃ = (CH₃)₂N, OCH₃, CH₃, H, Br, CI, NO₂

which led to the formation of *N*-substituted pyrazoline derivatives **3-5(a-g)** (Figure 2). The structure of all compounds **3-5(a-g)** was confirmed by its spectral data. The IR spectrum of the compounds **3-5 (a-g)**, showed absorption band around from 1600 to 1688

 cm^{-1} due to C=O stretching vibration. The stretching band for aliphatic C-H group observed from 2800 to 2960 cm⁻¹. The aromatic -C=C and C=N stretching vibrations were observed between 1480 -1550 cm⁻¹ and 1550 - 1600 cm⁻¹ respectively.



Figure 2 — Structures of compounds 3-5(a-g) and their yield

The ¹H NMR of compounds **3-5(a-g)**, –NH proton signal around at δ 5.8 was not observed, which reveals that the substitution occurred at N1 position. The CH₂ protons of N-substituted pyrazoline derivatives appeared as a pair of doublets around at δ 3.7-3.5 and 3.3-3.0 ($J_{AB} = 17.4-17.4$ Hz, $J_{AX} = 11.4 - 11.4$ 11.1 Hz, $J_{BX} = 5.1-5.4$ Hz). The CH proton appeared as a multiplet around at δ 5.62– 5.29 (H_X) due to the vicinal coupling with two magnetically nonequivalent protons of the methylene group of the pyrazoline ring (H_A and H_B) and styryl group proton $(H_{\rm Y})$ as mentioned in the Figure 1. In the ¹³C NMR of compound 3-5(a-g), the chemical shift values corresponding to the carbonyl carbon appeared around at δ 164 - 167, which confirms the amide carbonyl group. Aromatic and other carbon atoms were observed at expected chemical shift ranges. The structures of compound 3-5(a-g) and the corresponding yield is mentioned in the Figure 2.

The single crystals were obtained for one of the compounds, (3-benzo[b]thiophene-2-yl)-5-styryl-4,5dihydro-1*H*-pyrazol-1-yl)phenyl)methanone **3d** from saturated methanol solution. The single crystal X-ray diffraction analysis of compound **3d** shows the threedimensional structure of the molecules (CCDC number 2089498). Ortep diagram was generated and shown in Figure 3. The crystalline state along with their intermolecular interactions is shown in Figure 4 (Ref. 24). From the single crystal analysis, it was found that the compound **3d** having a monoclinic system with the lattice parameters, a=5.8842Å, b=23.776Å, c=14.982Å and α =90°, β =90.903° and γ =90°. Crystal data and refinement details are mentioned in Table I.

Pharmacology

Antioxidant activity

Free radicals such as reactive nitrogen species (RNS) and reactive oxygen species (ROS), including hydrogen peroxide, reactive hydroxyl radicals are produced by normal cellular metabolism and causes various diseases such as cancer. diabetes. cardiovascular disorders, neurodegenerative diseases, inflammation, age related diseases and osteoporosis. The excessive production of such ROS/RNS species in living cells originates the oxidative stress condition, where oxidants overpower the antioxidant productive system which may lead to imbalance between the production of antioxidants and the production of free radicals. This would cause damage

to lipids, protein, DNA resulting in an alteration of cell structures and functions and thus may lead to various diseases²⁵. The risk of such chronic diseases can be controlled by antioxidants. Antioxidants are compounds that can interact with free radicals in a safer manner, terminate the reaction, and convert them to a harmless molecule by offering an electron. Antioxidants therefore reduce the oxidative stress and



Figure 3 — Ortep diagram of compound 3d, showing 50% probability ellipsoids and the atom numbering scheme



Figure 4 — (a) Packing diagram of molecule **3d** and (b) dash lines indicates intermolecular interactions

thus protecting the cells from oxidative damage 26 . Phytochemicals such as vitamins, polyphenols, carotenoids and flavonoids are known as scavengers of free radicals²⁷.

The antioxidant activity of organic compounds can be assessed using various methods such as DPPH assay, hydroxyl radical scavenging (HRS) activity, super oxide anion radical and ABTS assay. In this study, the newly synthesized compounds were assessed with hydroxyl radical scavenging (HRS) activity. Hydroxyl radical is one of the potent reactive oxygen species in the biological system. It reacts with polyunsaturated fatty acid moieties of cell membrane phospholipids and cause damage to cell²⁸.

The antioxidant activity of the newly synthesized was determined with compounds various concentrations according to the method reported by Klein et al.²⁹ The results were tabulated in Table II, Table III and Table IV.

The percentage of inhibition was determined and tabulated for all the compounds **3-5(a-g)**.

% of inhibition

(Absorbance of control – Absorbance of test sample) $\times 100$ _ Absorbance of control

Structure activity relationship (SAR)

All the compounds were measured for percentage inhibition activity for HRS at different concentration

Table I — Crystal data and structure refinement details for compound 3d					
Identification code		Shelx			
Empirical formula	C ₂₆ H ₂₀ N ₂ O S				
Formula weight	408.5				
Temperature	296(2) K				
Wavelength	1.54178 Å				
Crystal system	Monoclinic				
Space group	P 21/n				
Unit cell dimensions	a = 5.8842(8) Å	$\alpha = 90^{\circ}$.			
	b = 23.776(3) Å	$\beta = 90.903(6)^{\circ}.$			
	c = 14.982(2) Å	$\gamma = 90^{\circ}.$			
Volume	2095.8(5) Å3				
Z	4				
Density (calculated)	1.295 Mg/m^3				
Absorption coefficient	1.521 mm^{-1}				
F(000)	856				
Crystal size	$0.300 \times 0.250 \times 0.200 \text{ mm}3$				
Theta range for data collection	3.487 to 72.282°.				
Index ranges	-7<=h<=7, -29<=k<=29, -18<=	=1<=18			
Reflections collected	43245				
Independent reflections	4133 [R(int) = 0.0687]				
Completeness to theta = 67.679°	100.00%				
Absorption correction	Multi				
Max. and min. transmission	0.7536 and 0.5740				
Refinement method	Full-matrix least-squares on F2				
Data / restraints / parameters	4133 / 81 / 271				
Goodness-of-fit on F2	1.03				
Final R indices [I>2sigma(I)]	R1 = 0.0386, wR2 = 0.1009				
R indices (all data)	R1 = 0.0692, wR2 = 0.1067				
Largest diff. peak and hole	0.125 and -0.297 e.Å-3				

Table II — Antioxidant activity of compounds **3(a-g)** by hydroxyl radical scavenging assay

Sample Concentration		Η	Percentage o	f inhibition	3(a-g)		
	$(CH_3)_2N$	OCH_3	CH_3	Н	Br	Cl	NO_2
	3 a	3b	3c	3d	3e	3f	3g
20 µg	12.18	5.77	31.41	11.54	1.92	16.67	3.21
40 µg	32.69	17.95	43.59	21.79	10.9	25	10.9
60 µg	51.92	35.26	50.64	28.21	41.67	42.95	26.92
80 µg	62.18	64.74	71.15	33.97	49.36	71.79	38.46
100 µg	73.08	78.85	81.41	42.31	62.82	85.26	58.97

Tab	le III — Antioxi	dant activity of	compounds 4(a	g) by hydroxyl	radical scaveng	ing assay	
	Percentage of inhibition 4(a-g)						
Sample Concentration	$(CH_3)_2N$	OCH_3	CH_3	Н	Br	Cl	NO_2
	4 a	4b	4c	4d	4e	4 f	4g
20 µg	8.33	1.92	11.54	3.21	1.92	4.49	0.64
40 µg	45.51	10.26	24.36	8.97	17.95	19.23	12.82
60 µg	53.21	17.95	35.26	23.08	37.18	36.54	19.23
80 µg	66.03	34.62	69.23	39.1	66.03	62.18	24.36
100 µg	84.62	37.18	76.28	57.69	84.62	86.54	55.13
Tab	le IV — Antioxi	idant activity of	compounds 5(a	-g) by hydroxyl	radical scaveng	ing assay	
	Percentage of inhibition 5(a-g)						
Sample Concentration	$(CH_3)_2N$	OCH_3	CH ₃	Н	Br	Cl	NO_2
	5a	5b	5c	5d	5e	5f	5g
20 µg	2.56	26.92	56.41	36.54	25.64	23.08	18.59
40 µg	37.18	50	58.97	48.08	37.18	46.79	35.26
60 µg	51.92	62.18	68.59	69.23	51.28	64.1	62.18
80 µg	55.13	65.38	73.08	71.15	64.1	67.95	75.64
100 µg	62.18	76.92	81.41	85.9	83.33	79.49	92.31



Figure 5 — Comparison of HRS activity of compounds 3(a-g) at different concentrations



Figure 6 — Comparison of HRS activity of compounds 4(a-g) at different concentrations

levels from 20 µg to 100 µg. The results of antioxidant activity of all compounds based on the electron donating and electron withdrawing group in the *para* position of the benzoyl group and the presence CF_3 in *para* and *meta* position of the styryl group have been studied and all the compounds have exhibited significant effect on the HRS activity.

All the compounds at high concentration level $(100 \ \mu g)$ showed excellent inhibition effects except unsubstituted compounds showing that the substitution plays an important role in the inhibition activity. Compounds bearing electron releasing groups (**3a**, **3b**, **3c**) and Cl (**3f**) were exhibited good

HRS activity and -Br (3e) and $-NO_2$ (3d) exhibited moderate HRS activity than the compound 3d (Figure 5). It reveals that the presence of substituents in the *para* position of the benzoyl group shows significant changes in the HRS activity irrespective of electron donating and electron withdrawing nature.

Similarly, in the *p*-trifluoromethyl styryl series, the compounds **4a**, **4e**, **4f** exhibited excellent HRS activity (Figure 6), at highest concentration level (100 μ g) than the compound **3a**, **3e** and **3f**. It is observed that the introduction of CF₃ at *para* position of styryl group did not affect much on HRS activity.

KRISHNAN et al.: N-SUBSTITUTED PYRAZOLINE DERIVATIVES



Figure 7 — Comparison of HRS activity of compounds 5(a-g) at different concentrations

In the *m*-trifluoromethyl styryl series, almost all the compounds exhibited excellent inhibition effect at maximum concentration level except the compound with $N(Me)_2$ substituent (5a). The introduction of CF_3 group at *m*-position of the styryl group enhances the inhibitory activity when compared to *p*-CF₃ substituted and unsubstituted series. The HRS activity of compound 5g shows superior activity than the 3g and 4g, proves that the presence of CF_3 groups enhances the activity than the other compounds (Figure 7).

As whole, compounds 3c, 3f, 4a, 4e, 4f, 5c, 5d, 5e and 5g shows good antioxidant property than the other compounds. Compound 5g is more potent inhibition of hydroxyl radical than the other compounds. The above study indicates that the presence of substitution in the benzoyl ring and CF_3 substitution in the styryl group shows significant changes in the HRS activity.

Experimental Section

The reagents were purchased from Aldrich and used without further purification and solvents were purchased from commercial suppliers and used without further purification. ¹H NMR and ¹³C NMR spectra were obtained on a Bruker Avance instrument in CDCl₃ using TMS as an internal standard, operating at 300 MHz and 75 MHz respectively. Chemical shifts (δ) are expressed in ppm and coupling constants J are given in Hz. For CDCl₃ solutions the chemical shifts are reported as parts per million (ppm) to residual proton or carbon of the solvents; CDCl₃ $(\delta_{\rm H} 7.26)$ and CDCl₃ ($\delta_{\rm C} 77.03$). Multiplicities are reported using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet,dd = doublet of doublets, m = multiplet. UV-Vis spectra were recorded between 200 to 800 nm on Shimadzu (1650) UV-Vis spectrophotometer using CH₂Cl₂ as solvent. IR spectra were collected neat in the solid state on a Bruker Spectrum-1. Melting points were obtained on a Melting point instrument. LC-MS spectra were obtained on Thermoscientific LTQ Xcallibur 2.2 LCMS spectrometer equipped with an ESI/APCI source.

General procedure for the preparation of compounds 1a-c

Synthesis of 1-(benzo[b]thiophen-2-yl)-5phenylpenta-2,4-dien-1-one, 1a

A mixture of cinnamaldehyde (20.0 g, 0.151 mol), 1-benzo[b]thiophen-2-yl-ethanone (22.7 g, 0.129 mol) in absolute alcohol (150.0 mL) and demineralized water (75 mL) was stirred under drop wise addition of 20% NaOH solution (25.0 mL, 0.125 mol) at 10-15°C for 30 minutes. The reaction mixture was stirred for 60 minutes at 25-30°C and completion of the reaction was confirmed by TLC. Upon reaction completion the precipitated solid was filtered, washed with 1:1 mixture of ethanol and water (50.0 mL). The crude product was purified using ethanol (40.0 mL) to obtain 1a. Yellow solid. Yield 65%. m.p. 130-132°C. UV-Vis (CH₂Cl₂): λ max (ϵ) = 356 nm; IR (KBr): 3053-3026, 1640, 1582, 1515-1430, 1353, 1187-1144, 1000 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.04 (s, 1H), 7.92-7.87 (m, 2H), 7.72-7.64 (m, 1H), 7.53-7.33 (m, 8H), 7.14-7.04 (m, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 178.72, 140.59, 139.63, 137.89, 137.83, 134.58, 131.32, 124.64, 124.16, 123.86, 122.66, 122.60, 121.92, 121.22, 120.26, 119.74 and 118.26; LC-MS: m/z 291.10 [M+H]. Anal. Calcd for: C₁₉H₁₄OS: C, 78.59; H, 4.86. Found: C, 78.58; H, 4.84%.

1-(Benzo[b]thiophen-2-yl)-5-(4-(trifluoromethyl) phenyl)penta-2,4-dien-1-one, 1b: Yellow solid. Yield 65% (24.4 g). m.p.166-168°C. UV-Vis (CH₂Cl₂): λ_{max} (ε) = 348 nm; IR (KBr): 3064, 1638-1612, 1581, 1577, 1514-1416, 1323, 1148, 1065 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.04 (s, 1H), 7.93-7.88 (m, 2H), 7.70 (m, 5H), 7.51-7.39 (m, 2H), 7.19-7.02 (m, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 183.26, 145.10, 143.31, 142.70, 140.26, 139.40, 139.38, 139.27, 131.33, 130.90, 130.47, 130.04, 129.40, 128.91, 128.88, 127.51, 127.39, 126.02, 125.87, 125.82, 125.77, 125.72, 125.09, 123.00, 122.19 and 118.59; LC-MS: m/z 359.13 [M+H]. Anal. Calcd for: $C_{20}H_{13}F_{3}OS$: C, 67.03; H, 3.66. Found: C, 67.01; H, 3.64%.

1-(Benzo[b]thiophen-2-yl)-5-(3-(trifluoromethyl) phenyl)penta-2,4-dien-1-one, 1c: Yellow solid. Yield 65% (11.6 g). m.p.154-156°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ) = 346 nm; IR (KBr): 3053-3018, 1640, 1581, 1515-1429, 1325, 1121, 1006 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 8.04 (s, 1H), 7.93-7.88 (m, 2H), 7.76 (s, 1H), 7.70-7.76 (m, 3H), 7.54-7.39 (m, 3H), 7.19-7.02 (m, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 183.29, 145.12, 143.35, 142.69, 140.27, 139.27, 136.80, 132.00, 131.5, 131.1, 130.7, 130.42, 129.3, 129.07, 128.8, 128.3, 127.4, 126.02, 125.7, 125.66, 125.58, 125.5, 125.06, 123.79, 123.64, 122.99, 122.14 and 118.52; LC-MS: m/z 359.15 [M+H]. Anal. Calcd for: C₂₀H₁₃F₃OS: C, 67.03; H, 3.66. Found: C, 67.02; H, 3.65%.

General procedure for the preparation of compounds 2a-c

Synthesis of 3-(benzo[b]thiophen-2-yl)-5-styryl-4.5-dihvdro-1*H*-pyrazole, 2a: A mixture of compound 1a (21.0 g, 0.072 mol) in absolute alcohol (100.0 mL) and hydrazine monohydrate (7.24 g, 0.145 mol) were heated to 75-80°C and maintained for 7 hours. The progress of the reaction was monitored by TLC. Upon reaction completion the reaction mixture was cooled to 0-5°C. The precipitated solid was filtered, washed with ethanol (40.0 mL). The crude product was purified using methanol (50.0 mL) to obtain compound 2a. Pale yellow solid. Yield 77%. m.p.136-138°C. UV-Vis (CH2Cl2): λmax (ϵ) = 325 nm; IR (KBr): 3331, 3053-3022, 2895-2858, 1642, 1522-1494, 1437, 1354, 1180-1158, 1032, 974 cm⁻¹; 1H NMR (300 MHz, CDCl₃): δ 7.80-7.70 (m, 2H), 7.40-7.22 (m, 8H), 6.62-6.57 (d, 1H, J = 15.6), 6.35-6.27 (dd, 1H, $J_1 = 15.6$ Hz, $J_2 = 8.4$ Hz), 5.82 (bs, 1H), 4.62-4.53 (dd, 1H, $J_1 = 17.7$ Hz, $J_2 = 8.4$ Hz), 3.39-3.30 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 9.9$ Hz), 3.05-2.97 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 8.4$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 143.36, 135.27, 134.95, 132.21, 131.51, 127.45, 123.94, 123.83, 123.27, 121.78, 120.50, 119.77, 119.02, 118.33, 117.65, 59.20 and 34.61; LC-MS: m/z 305.18 [M+H]. Anal. Calcd for: C₁₉H₁₆N₂S: C, 74.97; H, 5.30; N, 9.20. Found: C, 74.95; H, 5.28; N, 9.19%.

3-(Benzo[b]thiophen-2-yl)-5-(4-(trifluoromethyl) styryl)-4,5-dihydro-1H-pyrazole, 2b: Pale yellow solid. Yield 80% (14.2 g). m.p.174-176°C. UV-Vis (CH_2Cl_2) : λ_{max} (ϵ) = 318 nm; IR (KBr): 3332, 3262, 3052, 2866, 1613, 1414, 1329, 1160, 1115, 1067, 1037 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.82-7.70 (m, 2H), 7.59-7.46 (m, 5H), 7.37-7.26 (m, 4H), 6.66-6.60 (d, 1H, J = 15.9 Hz), 6.44-6.36 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 8.4$ Hz), 5.87 (bs, 1H), 4.65-4.56 (dd, 1H, $J_1 = 18.0$ Hz, $J_2 = 8.4$ Hz), 3.42-3.33 (dd, 1H, , $J_1 = 15.9$ Hz, $J_2 = 9.9$ Hz), 3.06-2.98 (dd, 1H, , $J_1 = 15.9$ Hz, $J_2 = 8.4$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 148.13, 140.02, 139.73, 139.64, 136.71, 131.25, 130.80, 130.42, 129.99, 129.56, 129.13, 126.69, 125.92, 125.71, 125.66, 125.61, 125.56, 125.35, 125.24, 124.57, 123.80, 123.23, 123.03, 122.40, 122.31, 63.65 and 39.34; LC-MS: m/z 373.17 [M+H]. Anal. Calcd for: C₂₀H₁₅F₃N₂S: C, 64.50; H, 4.06; N, 7.52. Found: C, 64.51; H, 4.05; N, 7.51%.

3-(Benzo[b]thiophen-2-yl)-5-(3-(trifluoromethyl) styryl)-4,5-dihydro-1H-pyrazole, 2c: Pale yellow solid. Yield 80% (8.3 g). m.p.147-149°C. UV-Vis $(CH_2Cl_2): \lambda_{max}$ (ϵ) = 319 nm; IR (KBr): 3324, 3063-3039, 2919-2864, 1661, 1523-1493, 1338, 1115, 1029 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 7.83-7.77 (m, 1H), 7.77-7.70 (m, 1H), 7.62 (s, 1H), 7.56-7.40 (m, 3H), 7.36-7.31 (m, 2H), 7.27 (s, 1H), 6.65-6.60 (d, 1H, J = 15.9 Hz), 6.42-6.34 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 8.1$ Hz), 5.84 (bs, 1H), 4.64-4.55 (dd, 1H, $J_1 = 18.3$ Hz, $J_2 = 8.4$ Hz), 3.41-3.32 (dd, 1H, , $J_1 = 15.9$ Hz, $J_2 = 9.9$ Hz), 3.06-2.97 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 8.4$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 148.11, 140.01, 139.66, 137.07, 136.74, 131.74, 131.32, 130.89, 130.74, 130.59, 130.46, 129.64, 129.14, 125.86, 125.32, 124.56, 124.52, 124.47, 124.42, 124.31, 123.80, 123.29, 123.22, 123.14, 122.39, 122.25, 118.2, 63.63 and 39.31; LC-MS: m/z 373.18 [M+H]. Anal. Calcd for: C₂₀H₁₅F₃N₂S: C, 64.50; H, 4.06; N, 7.52. Found: C, 64.48; H, 4.05; N, 7.51%.

General procedure for the preparation of compounds 3-5a-g

Synthesis of (3-(benzo[b]thiophen-2-yl)-5-styryl-4,5-dihydro-1*H*-pyrazol-1-yl)(4-(dimethylamino) phenyl)methanone, 3a

A mixture of compound 2a (1.0 g, 0.003 mol) in dichloromethane (15 mL) with triethylamine (0.698 g, 0.007 mol) was cooled to 0-5°C. 4-dimethyl amino benzoyl chloride (1.206 g, 0.006 mol) was slowly

added to the reaction mixture for 10 minutes. The progress of the reaction was monitored by TLC. Upon reaction completion, reaction mixture was quenched using chilled water (15 mL) and layer was separated. Organic layer was washed with 5% sodium bicarbonate solution (15 mL) followed by water (15 mL) and organic layer was dried over sodium sulphate and evaporated to dryness. The product was crystallized from the residue using methanol (10 mL). The crystallized product was filtered and dried to obtain compound 3a. yellow solid. Yield 67.4%. m.p. 173-175°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ)= 336 nm; IR (KBr): 3053-3026, 2918-2818, 1750, 1688, 1639-1602, 1527-1491, 1392-1361, 1314, 1247, 1158, 1012 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 8.15-8.10 (m, 2H), 7.83-7.74 (m, 2H), 7.43-7.20 (m, 8H), 6.73-6.64 (m, 3H), 6.38-6.30 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.2$ Hz), 5.60-5.52 (m, 1H), 3.65-3.55 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 11.4$ Hz), 3.21-3.14 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 5.1$ Hz), 3.05 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 163.43, 154.08, 149.66, 140.58, 139.52, 136.40, 135.83, 132.58, 132.49, 131.74, 128.50, 127.79, 127.41, 126.71, 125.92, 125.31, 124.75, 124.19, 122.40, 120.59, 115.66, 110.85, 110.46, 60.20, 40.11 and 38.52; LC-MS: m/z 452.33 [M+H]. Anal. Calcd for: C₂₈H₂₅N₃OS: C, 74.47; H, 5.58; N, 9.31. Found: C, 74.46; H, 5.57; N, 9.30%.

(3-(Benzo[b]thiophen-2-yl)-5-styryl-4,5-dihydro-1*H*-pyrazol-1-yl)(4-methoxyphenyl)methanone, 3b: light pink solid. Yield 68% (0.98 g). m.p. 182-184°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ) = 334nm; IR (KBr): 3053-3007, 2961-2930, 2834, 1615, 1524-1506, 1444, 1403, 1332-1302, 1253, 1175, 1027 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.14-8.09 (m, 2H), 7.82-7.76 (m, 2H), 7.45 (s, 1H), 7.40-7.19 (m, 8H), 6.99-6.94 (m, 2H), 6.75-6.70 (d, 1H, J = 15.9 Hz), 6.37-6.30(dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.2$ Hz), 5.59-5.51 (m, 1H), 3.89 (s, 3H), 3.68-3.59 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 11.4$ Hz), 3.25-3.18 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 165.78, 161.10, 150.39, 140.63, 139.43, 136.23, 135.45, 132.53, 132.14, 128.54, 127.93, 126.91, 126.71, 126.23, 126.09, 125.68, 124.82, 124.25, 122.45, 113.01, 60.10, 55.38 and 38.75; LC-MS: m/z 439.27 [M+H]. Anal. Calcd for: C₂₇H₂₂N₂O₂S: C, 73.95; H, 5.06; N, 6.39. Found: C, 73.91; H, 5.01; N, 6.43%.

(3-(Benzo[b]thiophen-2-yl)-5-styryl-4,5-dihydro-1*H*-pyrazol-1-yl)(p-tolyl)methanone, 3c: Off-White solid. Yield 69.1% (0.96 g). m.p. 184-186°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ) = 331nm; IR (KBr): 3029, 2971-2923, 1633, 1568, 1520-1492, 1443-1413, 1322, 1185-1155, 1124, 1071-1020 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.99-7.25 (m, 14H), 6.77-6.72 (d, 1H, *J* = 15.6 Hz), 6.46-6.38 (dd, 1H, *J*₁ = 15.6 Hz, *J*₂ = 6.9 Hz), 5.60-5.52 (m, 1H), 3.71-3.61 (dd, 1H, *J*₁ = 17.4Hz, *J*₂ = 11.4Hz), 3.26-3.18 (dd, 1H, *J*₁ = 17.4 Hz, *J*₂ = 5.1 Hz), 2.42 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 166.44, 150.55, 141.58, 140.67, 139.42, 136.23, 135.42, 132.19, 131.20, 130.45, 128.57, 128.44, 127.96, 126.82, 126.73, 126.11, 125.75, 124.83, 124.27, 122.46, 60.01, 38.85, and 21.61; LC-MS: *m/z* 423.27 [M+H]. Anal. Calcd for: C₂₇H₂₂N₂OS: C, 76.75; H, 5.25; N, 6.63. Found: C, 76.73; H, 5.24; N, 6.61%.

(3-(Benzo[b]thiophen-2-yl)-5-styryl-4,5-dihydro-1*H*-pyrazol-1-yl)(phenyl)methanone, **3d**: White solid. Yield 74.5% (1.0 g). m.p. 156-158°C. UV-Vis $(CH_2Cl_2): \lambda_{max} (\epsilon) = 332$ nm; IR (KBr): 3059, 3026, 2981-2926, 1633, 1520-1492, 1448-1410, 1322, 1187-1154, 1126, 1071, 1021 cm^{-1} ; ¹H NMR (300) MHz, CDCl₃): δ 8.05-8.03 (m, 2H), 7.81-7.76 (m, 2H), 7.53-7.43 (m, 4H), 7.41-7.35 (m, 4H), 7.34-7.20 (m, 3H), 6.76-6.71 (d, 1H, J = 15.9 Hz), 6.37-6.30(dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.2$ Hz), 5.59-5.52 (m, 1H), 3.70-3.61 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 11.1$ Hz), 3.27-3.20 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75) MHz, CDCl₃): δ 166.50, 150.81, 140.69, 139.39, 136.20, 135.30, 134.13, 132.32, 131.18, 130.31, 128.59, 128.01, 127.73, 126.75, 126.68, 126.16, 125.88, 124.85, 124.30, 122.48, 59.98 and 38.94; LCm/z 409.28 [M+H]. Anal. Calcd for: MS: C₂₆H₂₀N₂OS: C, 76.44; H, 4.93; N, 6.86. Found: C, 76.43; H, 4.91; N, 6.85%.

(3-(Benzo[b]thiophen-2-yl)-5-styryl-4,5-dihydro-1*H*-pyrazol-1-yl)(4-bromophenyl)methanone, 3e: Off White solid. Yield 65.6% (1.05 g). m.p. 206-208°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ) = 330 nm; IR (KBr): 3040, 1785, 1623, 1526-1486, 1404-1418, 1324, 1177-1155, 1125, 1069, 1004 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.95-7.92 (m, 2H), 7.83-7.77 (m, 2H), 7.62-7.58 (m, 2H), 7.48 (s, 1H), 7.41-7.23 (m, 7H), 6.74-6.77 (d, 1H, J = 15.9 Hz), 6.36-6.28(dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.2$ Hz), 5.58-5.50 (m, 1H), 3.72-3.62 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 11.4$ Hz), 3.285-3.211 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 165.40, 151.16, 140.69, 139.33, 136.05, 135.03, 132.90, 132.58, 131.97, 130.96, 128.59, 128.08, 126.73, 126.36, 126.28, 126.09, 125.91, 124.90, 124.33, 122.49, 60.06 and 38.97; LC-MS: *m/z* 487.19 [M+H]. Anal. Calcd for: C₂₆H₁₉BrN₂OS: C, 64.07; H, 3.93; N, 5.75. Found: C, 64.05; H, 3.95; N, 5.74%.

(3-(Benzo[b]thiophen-2-yl)-5-styryl-4,5-dihydro-1*H*-pyrazol-1-yl)(4-chlorophenyl)methanone, **3f**: Off White solid. Yield 66.6% (0.97 g). m.p. 178-180°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ) = 327 nm; IR (KBr): 3037, 2924,-2852, 1677, 1622, 1526-1485, 1445-1420, 1336-1302, 1177-1153, 1125-1109, 1089, 1015, 834 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.10-8.00 (m, 2H), 7.79-7.76 (m, 2H), 7.48-7.21 (m, 10H), 6.77-6.71 (d, 1H, J=15.9 Hz), 6.36-6.28 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.2$ Hz), 5.59-5.51 (m, 1H), 3.72-3.63 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 11.4$ Hz), 3.29-3.21 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 165.35, 151.11, 140.69, 139.32, 137.33, 136.04, 135.03, 132.58, 132.38, 131.78, 131.56, 128.88, 128.56, 128.06, 12797, 126.71, 126.35, 126.25, 126.04, 124.88, 124.30, 122.48, 60.05 and 39.0; LC-MS: m/z 443.29 [M+H]. Anal. Calcd for: C₂₆H₁₉ClN₂OS: C, 70.50; H, 4.32; N, 6.32. Found: C, 70.50; H, 4.30; N, 6.31%.

(3-(Benzo[b]thiophen-2-vl)-5-stvrvl-4.5-dihvdro-1*H*-pyrazol-1-yl)(4-nitrophenyl)methanone, 3g: Yellow solid. Yield 73.8% (1.1 g). m.p. 202-203°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ) = 257, 318 nm; IR (KBr): 3056, 3024-2844, 1632, 1596, 1519, 1445-1421, 1334, 1180-1158, 1123-1106, 1014 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.33-8.30 (m, 2H), 8.18-8.15 (m, 2H), 7.83-7.78 (m, 2H), 7.51-7.25 (m, 8H), 6.80-6.75 (d, 1H, J = 15.6 Hz), 6.36-6.29 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.5$ Hz), 5.60-5.52 (m, 1H), 3.77-3.67 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 11.1$ Hz), 3.34-3.26 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 164.37, 152.03, 149.06, 140.74, 139.99, 139.36, 135.89, 134.58, 133.08, 131.17, 128.65, 128.24, 126.76, 126.60, 126.49, 125.86, 12501, 124.44, 122.86, 122.52, 60.11 and 39.18; LC-MS: m/z 454.23 [M+H]. Anal. Calcd for: C₂₆H₁₉N₃O₃S: C, 68.86; H, 4.22; N, 9.27. Found: C, 68.85; H, 4.21; N, 9.26%.

(3-(Benzo[b]thiophen-2-yl)-5-(4-(trifluoromethyl) styryl)-4,5-dihydro-1*H*-pyrazol-1-yl)(4-(dimethy

lamino)phenyl)methanone, 4a: Pale yellow solid. Yield 70.2% (0.98 g). m.p. 191-194°C. UV-Vis (CH₂Cl₂): λ_{max} (ε) = 310 nm; IR (KBr): 3057, 2990-2819, 1916, 1731, 1625-1602, 1527, 1394, 1321, 1160, 1112, 1065, 1013 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.11-8.01 (d, 2H), 7.83-7.76 (m, 2H), 7.63-7.34 (m, 7H), 6.76-6.56 (m, 3H), 6.46-6.38 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 6.9$ Hz), 5.62-5.54 (m, 1H), 3.69-3.59 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 11.4$ Hz), 3.23-3.16 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 5.4$ Hz), 3.06 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 166.07, 152.43, 149.63, 140.59, 139.91, 139.46, 135.63, 132.57, 132.50, 130.39, 130.11, 129.72, 129.29, 126.84, 125.99, 125.50, 125.45, 125.40, 124.79, 124.19, 122.41, 120.30, 60.04, 40.08, 40.02 and 38.44; LC-MS: m/z 520.30 [M+H]. Anal. Calcd for: $C_{29}H_{24}F_3N_3OS$: C, 67.04; H, 4.66; N, 8.09. Found: C, 67.03; H, 4.64; N, 8.09%.

(3-(Benzo[b]thiophen-2-yl)-5-(4-(trifluoro methyl)styryl)-4,5-dihydro-1*H*-pyrazol-1-yl)(4-

methoxyphenyl)methanone, 4b: Pale brown solid. Yield 75% (1.02 g). m.p. 118-120°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ) = 332 nm; IR (KBr): 3057, 2999-2836, 1905, 1629-1, 1509, 1487, 1444, 1404, 1312, 1252, 1155, 1125, 1060, 1033 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.10-8.00 (m, 2H), 7.78-7.76 (m, 2H), 7.63-7.60 (m, 2H), 7.48-7.30 (m, 5H), 7.12-7.07 (m, 1H), 7.0-6.95 (m, 2H), 6.41-6.33 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 6.9$ Hz), 5.62-5.54 (m, 1H), 3.89 (s, 3H), 3.73-3.63 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 11.4$ Hz), 3.28-3.20 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 5.4$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 165.96, 162.02, 150.24, 140.67, 139.40, 135.47, 135.30, 132.47, 131.83, 131.67, 127.94, 127.69, 127.56, 126.09, 125.78, 125.69, 124.81, 124.25, 122.44, 113.01, 59.88, 55.37 and 38.68.; LC-MS: *m/z* 507.31 [M+H]. Anal. Calcd for: C₂₈H₂₁F₃N₂O₂S: C, 66.39; H, 4.18; N, 5.53. Found: C, 66.37; H, 4.16; N, 5.52%.

(3-(Benzo[b]thiophen-2-yl)-5-(4-(trifluorometh yl)styryl)-4,5-dihydro-1*H*-pyrazol-1-yl)(p-

tolyl)methanone, 4c: Off-White solid. Yield 73% (0.96 g). m.p. 177-179°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ) = 256, 331 nm; IR (KBr): 3054, 2979-2920, 1920, 1649, 1520, 1408, 1324, 1157, 1123, 1067, 1014 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.98-7.95 (d, 2H, J = 8.4 Hz), 7.81-7.74 (m, 2H), 7.45-7.19 (m, 9H), 6.75-6.70 (d, 1H, J = 15.6 Hz), 6.37-6.29 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.2$ Hz), 5.59-5.29 (m, 1H), 3.69-3.59 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 11.4$ Hz), 3.25-3.18 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 5.1$ Hz), 2.42 (s, 3H); 1³C NMR (75 MHz, CDCl₃): δ 166.48, 150.54, 141.76, 140.67, 139.71, 139.36, 135.20, 130.96, 130.84, 130.44, 130.31, 130.09, 129.88, 129.58, 129.50, 129.11, 129.02, 128.74, 128.47, 126.87, 126.19, 125.97, 125.85, 125.56, 125.51, 125.46, 125.41, 124.87, 124.28, 122.46, 122.37, 59.84, 38.77 and 21.58; LC-MS: m/z 491.3 [M+H]. Anal. Calcd for: $C_{28}H_{21}F_{3}N_{2}OS$: C, 68.56; H, 4.32; N, 5.71. Found: C, 68.54; H, 4.30; N, 5.70%.

(3-(Benzo[b]thiophen-2-yl)-5-(4-(trifluoromethyl) styryl)-4,5-dihydro-1H-pyrazol-1-yl) (phenyl) methanone, 4d: White solid. Yield 78% (1.0 g). m.p. 134-136°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ) = 256, 336 nm; IR (KBr): 3060, 2927, 1918, 1633, 1522, 1448, 1412, 1324, 1158, 1122, 1066, 1015 cm⁻¹; ¹H NMR (300 MHz CDCl₃): δ 8.06-8.03 (m, 2H), 7.83-7.75 (m, 2H), 7.56-7.26 (m, 8H), 6.79-6.74 (d, 1H, J=15.9 Hz), 6.47-6.39 (dd, 1H, $J_1 = 15.6$ Hz, $J_2 = 6.9$ Hz), 5.61-5.54 (m, 1H), 3.74-3.65 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 11.4$ Hz), 3.29-3.21(dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 166.56, 150.77, 140.70, 139.66, 139.33, 135.08, 133.87, 131.31, 130.98, 130.29, 129.32, 127.76, 126.88, 126.23, 125.97, 125.54, 125.49, 124.88, 124.30, 122.48, 59.79, 38.88; LC-MS: m/z 477.27 [M+H]. Anal. Calcd for: C₂₇H₁₉F₃N₂OS: C, 68.06; H, 4.02; N, 5.88. Found: C, 68.04; H, 4.01; N, 5.89%.

(3-(Benzo[b]thiophen-2-yl)-5-(4-(trifluoromet hyl)styryl)-4,5-dihydro-1*H*-pyrazol-1-yl)(4-

bromophenyl)methanone, 4e: Off White solid. Yield 73.7% (1.1 g). m.p. 180-182°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ) = 257, 329 nm; IR (KBr): 3062-2927, 1914, 1646, 1587, 1522, 1482, 1414, 1327, 1239, 1158, 1120, 1067, 1007 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.10-7.90 (m, 2H), 7.82-7.77 (m, 2H), 7.70-7.47 (m, 7H), 7.43-7.36 (m, 2H), 6.79-6.74 (d, 1H, J = 15.9Hz), 6.45-6.37 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.2$ Hz), 5.59-5.51 (m, 1H), 3.75-3.65 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 11.4$ Hz), 3.29-3.22 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 165.45, 151.13, 140.71, 139.55, 139.29, 134.82, 132.68, 132.39, 131.96, 131.92, 131.82, 131.22, 131.01, 130.21, 130.03, 129.60, 129.06, 127.53, 126.88, 126.36, 126.20, 126.07, 125.92, 125.56, 125.51, 125.46, 124.95, 124.35, 122.50, 122.32, 59.90 and 38.89; LC-MS: m/z 557.2 [M+H]. Anal. Calcd for: C₂₇H₁₈BrF₃N₂OS: C, 58.39; H, 3.27; N, 5.04. Found: C, 58.38; H, 3.25; N, 5.05%.

(3-(Benzo[b]thiophen-2-yl)-5-(4-(trifluoromethy l)styryl)-4,5-dihydro-1*H*-pyrazol-1-yl)(4-

chlorophenyl)methanone, 4f: White solid. Yield 80% (1.1 g). m.p. 168-170°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ) = 255, 327 nm; IR (KBr): 3057, 2926, 1924, 1786,

1721, 1648, 1591, 1523, 1485, 1415, 1327, 1241, 1159, 1122-1070, 1009, 837 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.10-8.00 (m, 2H), 7.83-7.76 (m, 9H), 6.79-6.74 (d, 1H, J = 15.6 Hz), 6.45-6.38 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.2$ Hz), 5.60-5.54 (m, 1H), 3.75-3.65 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 11.4$ Hz), 3.29-3.22 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 165.35, 151.11, 141.42, 140.70, 139.56, 139.30, 137.49, 134.84, 132.20, 131.88, 131.80, 131.20, 130.02, 129.59, 129.38, 129.10, 128.71, 128.02, 127.09, 126.88, 126.35, 126.19, 125.92, 125.55, 125.50, 125.45, 124.94, 124.35, 122.49, 122.32, 59.90, 38.88; LC-MS: *m/z* 511.20 [M+H]. Anal. Calcd for: C₂₇H₁₈ClF₃N₂OS: C, 63.47; H, 3.55; N, 5.48. Found: C, 63.46; H, 3.54; N, 5.47%.

(3-(Benzo[b]thiophen-2-yl)-5-(4-(trifluorom ethyl)styryl)-4,5-dihydro-1H-pyrazol-1-yl)(4nitrophenyl)methanone, 4g: Yellow solid. Yield 70.7% (0.99 g). m.p. 197-199°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ) = 260, 321 nm; IR (KBr): 3207, 3117-2849, 1940, 1624, 1595, 1519, 1444, 1419, 1324, 1158, 1123, 1066, 1015 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.34-8.29 (m, 2H), 8.19-8.15 (m, 2H), 7.83-7.78 (m, 2H), 7.58-7.26 (m, 7H), 6.84-6.78 (d, 1H, J = 15.9Hz), 6.46-6.38 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.5$ Hz), 5.61-5.53 (m, 1H), 3.80-3.70 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 11.1$ Hz), 3.35-3.27 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 164.43, 152.05, 149.12, 140.76, 139.75, 139.39, 139.22, 134.36, 131.71, 131.18, 130.17, 129.74, 128.56, 126.92, 126.73, 126.58, 125.61, 125.56, 125.51, 125.05, 124.47, 122.88, 122.53, 59.95 and 39.11; LC-MS: m/z522.2 [M+H]. Anal. Calcd for: C₂₇H₁₈F₃N₃O₃S: C, 62.18; H, 3.48; N, 8.06. Found: C, 62.17; H, 3.47; N, 8.04%.

(3-(Benzo[b]thiophen-2-yl)-5-(3-(trifluorometh yl)styryl)-4,5-dihydro-1*H*-pyrazol-1-yl)(4-

(dimethylamino)phenyl)methanone, 5a: Pale yellow solid. Yield 65% (0.9 g). m.p. 163-165°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ)= 231, 285 nm; IR (KBr): 3059, 2917-2819, 1688, 1568, 1524-1485, 1445-1414, 1327, 1118, 1071 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.05-8.05 (d, 2H), 7.76-7.69 (m, 2H), 7.47-7.37 (m, 5H), 7.34-7.27 (m, 2H), 6.69-6.58 (m, 3H), 6.41-6.33 (dd, 1H, J_1 = 15.9 Hz, J_2 = 6.9 Hz), 5.55-5.47 (m, 1H), 3.62-3.52 (dd, 1H, J_1 = 17.1 Hz, J_2 = 11.4 Hz), 3.15-3.08 (dd, 1H, J_1 = 17.1 Hz, J_2 = 5.4 Hz), 2.99 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 166.06, 152.43, 149.68, 140.59, 139.48, 137.19, 135.63, 132.56,

132.51, 131.51, 131.08, 130.66, 130.39, 130.23, 129.90, 129.41, 128.97, 125.99, 125.93, 125.44, 124.78, 124.3, 124.25, 124.22, 123.34, 123.24, 122.40, 122.32, 120.32, 118.71, 110.84, 110.45, 60.4, 40.07 and 38.45; LC-MS: m/z 520.34 [M+H]. Anal. Calcd for: C₂₉H₂₄F₃N₃OS: C, 67.04; H, 4.66; N, 8.09. Found: C, 67.03; H, 4.64; N, 8.07%.

(3-(Benzo[b]thiophen-2-yl)-5-(3-(trifluorom ethyl)styryl)-4,5-dihydro-1*H*-pyrazol-1-yl)(4-

methoxyphenyl)methanone, 5b: Pale brown solid. Yield 75% (1.0 g). m.p. 132-135°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ)= 245, 334 nm; IR (KBr): 3060-3000, 2961-2933, 2839, 1622, 1571, 1524-1511, 1422-1406, 1330, 1115, 1254, 1071cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.13-8.10 (m, 2H), 7.82-7.76 (m, 2H), 7.63 (s, 1H), 7.56-7.34 (m, 6H), 6.99-6.94 (m, 2H), 6.78-6.72 (d, 1H, J = 15.9 Hz), 6.44-6.37 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.2$ Hz), 5.60-5.52 (m, 1H), 3.89 (s, 3H), 3.70-3.60 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 11.1$ Hz), 3.25-3.18 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.4$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 165.82, 162.10, 150.44, 140.64, 139.39, 137.03, 135.25, 132.57,131.57, 131.14, 130.72, 130.29, 129.93, 129.52, 129.02, 128.92, 126.17, 126.02, 125.91, 125.83, 124.87, 124.45, 124.40, 124.29, 123.33, 123.23, 122.45, 122.30, 118.69, 113.06, 59.95, 55.36 and 38.67; LC-MS: m/z 507.31[M+H]. Anal. Calcd for: C₂₈H₂₁F₃N₂O₂S: C, 66.39; H, 4.18; N, 5.53. Found: C, 66.38; H, 4.17; N, 5.52%.

(3-(Benzo[b]thiophen-2-yl)-5-(3-(trifluorometh yl)styryl)-4,5-dihydro-1*H*-pyrazol-1-yl)(p-

tolyl)methanone, 5c: Off-White solid. Yield 73% (0.96 g). m.p. 159-160°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ)= 242, 333 nm; IR (KBr): 3064, 2963-2928, 1629, 1568, 1524-1485, 1445-1419, 1327, 1118, 1071 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 7.99-7.97 (d, 2H, J = 8.1 Hz), 7.82-7.76 (m, 2H), 7.64 (s, 1H), 7.56-7.54 (d, 1H, J = 7.8 Hz), 7.49-7.34 (m, 5H), 7.28-7.26 (d, 2H), 6.78-6.73 (d, 1H, J = 15.9 Hz), 6.45-6.37 (dd, 1H, $J_1 = 15.6$ Hz, $J_2 = 6.9$ Hz), 5.60-5.53 (m, 1H), 3.72-3.63 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 11.1$ Hz), 3.27-3.19 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.1$ Hz), 2.43 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 166.49, 150.48, 141.73, 140.68,139.36, 136.99, 135.23, 131.19, 130.95, 130.88, 130.76, 130.44, 129.93, 129.02, 128.77, 128.45, 126.16, 125.88, 125.80, 124.85, 124.48, 124.43, 124.26, 123.34, 123.29, 122.45, 122.27, 59.81, 38.81 and 21.58; LC-MS: m/z 491.27 [M+H]. Anal. Calcd for: C₂₈H₂₁F₃N₂OS: C, 68.56; H,

4.32; N, 5.71. Found: C, 68.55; H, 4.31; N, 5.70%.

(3-(Benzo[b]thiophen-2-yl)-5-(3-(trifluorometh yl)styryl)-4,5-dihydro-1*H*-pyrazol-1-

yl)(phenyl)methanone, 5d: White solid. Yield 70%. m.p. 160-162°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ)= 330 nm; IR (KBr): 3066, 2931, 1637, 1526-1490, 1416-1449, 1326, 1123, 1073 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.06-8.04 (m, 2H), 7.82-7.77 (m, 2H), 7.64 (s, 1H), 7.57-7.35 (m, 9H), 6.80-6.75 (d, 1H, J = 15.9 Hz), 6.45-6.38 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.2$ Hz), 5.62-5.54 (m, 1H), 3.74-3.65 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 11.4$ Hz), 3.29-3.22 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 166.55, 150.78, 140.71, 139.35, 136.97, 135.11, 133.90, 131.62, 131.29, 131.19, 130.99, 130.76, 130.32, 129.95, 129.51, 129.05, 128.65, 127.75, 126.22, 125.97, 125.90, 124.88, 124.52, 124.47, 124.31, 123.39, 123.34, 123.29, 123.24, 122.47, 122.29, 118.68, 59.80 and 38.88; LC-MS: *m/z* 477.20 [M+H]. Anal. Calcd for: C₂₇H₁₉F₃N₂OS: C, 68.06; H, 4.02; N, 5.88. Found: C, 68.04; H, 4.01; N, 5.87%.

(3-(Benzo[b]thiophen-2-yl)-5-(3-(trifluorom ethyl)styryl)-4,5-dihydro-1*H*-pyrazol-1-yl)(4-

bromophenyl)methanone, 5e: Off White solid. Yield 80% (1.2 g). m.p. 162-164°C. UV-Vis (CH₂Cl₂): λ_{max} $(\varepsilon) = 242, 318 \text{ nm}; \text{ IR (KBr)}: 3056, 2928, 1646, 1591,$ 1523-1485, 1446-1417, 1331, 1119, 1071 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 8.0-7.90 (d, 2H), 7.81-7.77 (m, 2H), 7.69-7.54 (m, 4H), 7.50-7.35 (m, 5H), 6.80-6.74 (d, 1H, J = 15.9 Hz), 6.43-6.35 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.2$ Hz), 5.59-5.51 (m, 1H), 3.74-3.65 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 11.4$ Hz), 3.29-3.22 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75) MHz, CDCl₃): δ 165.41, 151.18, 140.70, 139.31, 136.85, 134.84, 132.72, 132.00,131.62, 131.22, 131.01, 130.77, 130.34, 129.97, 129.50, 129.08, 128.39, 126.36, 126.24, 126.05, 125.89, 124.96, 124.65, 124.60, 124.55, 124.50, 124.38, 123.39, 123.34, 123.29, 123.24, 122.50, 122.28, 118.67, 59.92 and 38.88; LC-MS: m/z 557.17 [M+H]. Anal. Calcd for: C₂₇H₁₈BrF₃N₂OS: C, 58.39; H, 3.27; N, 5.04. Found: C, 58.38; H, 3.26; N, 5.02%.

(3-(Benzo[b]thiophen-2-yl)-5-(3-(trifluoromethy l) styryl)-4,5-dihydro-1*H*-pyrazol-1-yl)(4chlorophenyl)methanone, 5f: Off White solid. Yield 60% (0.82 g). m.p. 148-150°C. UV-Vis (CH₂Cl₂): λ_{max} (ϵ)= 242, 333 nm; IR (KBr): 3057, 2926-2851, 1645, 1593, 1523-1489,1446-1418, 1330, 1119, 1091, 835cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.04-8.0 (d, 2H), 7.83-7.77 (m, 2H), 7.64 (s, 1H), 7.57-7.35 (m, 8H), 6.80-6.75 (d, 1H, J = 15.9 Hz), 6.43-6.36 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.5$ Hz), 5.60-5.52 (m, 1H), 3.75-3.65 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 11.4$ Hz), 3.30-3.22 (dd, 1H, $J_1 = 17.1$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 165.35, 151.19, 140.70, 139.31, 137.48, 136.86, 134.84, 132.22, 131.84, 131.62, 131.22, 130.77, 130.34, 131.22, 129.96, 129.50, 129.07, 128.39, 128.03, 126.36, 126.24, 125.89, 124.95, 124.59, 124.50, 124.38, 123.39, 123.34, 123.29, 123.24, 122.50, 122.28, 118.67, 59.93 and 38.88; LC-MS: m/z 511.20 [M+H]. Anal. Calcd for: C₂₇H₁₈ClF₃N₂OS: C, 63.47; H, 3.55; N, 5.48. Found: C, 63.45; H, 3.54; N, 5.46%.

(3-(Benzo[b]thiophen-2-yl)-5-(3-(trifluorometh yl)styryl)-4,5-dihydro-1*H*-pyrazol-1-yl)(4-

nitrophenyl)methanone, 5g: Yellow solid. Yield 78% (1.1 g). m.p. 202-204°C. UV-Vis (CH₂Cl₂): λ_{max} $(\varepsilon) = 257, 322 \text{ nm}; \text{ IR (KBr): } 3104-3078, 2929-2847,$ 1649, 1600, 1519, 1492, 1449-1425, 1336, 1112, 1320, 1073cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.33-8.30 (d, 2H), 8.19-8.15 (d, 2H), 7.83-7.78 (m, 2H), 7.66 (s, 1H), 7.59-7.36 (m, 6H), 6.84-6.79 (d, 1H, J = 15.9 Hz), 6.44-6.36 (dd, 1H, $J_1 = 15.9$ Hz, $J_2 = 7.5$ Hz), 5.61-5.53 (m, 1H), 3.80-3.70 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 11.1$ Hz), 3.35-3.28 (dd, 1H, $J_1 = 17.4$ Hz, $J_2 = 5.1$ Hz); ¹³C NMR (75 MHz, CDCl₃): δ 164.45, 152.02, 149.13, 140.77, 139.76, 139.22, 136.67, 134.38, 131.76, 131.30, 131.20, 130.87, 130.01, 129.13, 127.83, 126.69, 126.56, 125.82, 125.03, 124.77, 124.45, 123.34, 123.29, 122.89, 122.53, 59.93 and 39.16; LC-MS: m/z 522.25 [M+H]. Anal. Calcd for: $C_{27}H_{18}F_3N_3O_3S$: C, 62.18; H, 3.48; N, 8.06. Found: C, 62.17; H, 3.47; N, 8.05%.

Conclusion

Novel N-substituted pyrazoline derivatives were synthesized from1-(benzo[b]thiophene-2-yl)ethan-1one and trifluoromethyl substituted cinnamaldehyde at *para*- and *meta*- positions by known methods and characterized by spectral techniques (NMR, Mass and IR). All the compounds show significant antioxidant property. Among them compounds **3c**, **3f**, **4a**, **4e**, **4f**, **5c**, **5d 5e** and **5g** shows good antioxidant property than the other compounds.

Supplementary Information

Supplementary information is available in the website http://nopr.niscair.res.in/ handle/123456789/ 58776.

Acknowledgements

The authors are very thankful to the Director, Solara Active Pharma Sciences Limited, Research Centre, Chennai for encouragement and support.

References

- 1 Karthikeyan M S, Holla B S & Kumari N S, *European J* Med Chem, 42 (2007) 30.
- 2 Havrylyuk D, Zimenkovsky B, Vasylenko 'O & Lesyk R, *J Heterocycl Chem*, 50 (2013) E55.
- 3 Joshi H S, Popat K H & Nimavt K S, Indian J Heterocycl Chem, 12 (2003) 225.
- 4 Drabu S, Rana A & Kumar H, *Indian J Heterocycl Chem*, 16 (2007) 399.
- 5 Shaharyar M, Abdullah M M, Bakht M A & Majeed J, *Eur J Med Chem*, 45 (2010) 114.
- 6 Tanwer N, Kaur R, Rana D & Singh R, J Integr Sci Technol, 3 (2015) 39.
- 7 Lombardino J G & Otterness I G, *J Med Chem*, 24 (1981) 830.
- 8 Joshi R S, Mandhane P G, Diwakar S D, Dabhade S K & Gill C H, *Bioorg Med Chem Lett*, 20 (2010) 3721.
- 9 (a) Ahluwalia V K, Dutt U & Sharma H R, J Indian Chem Soc, LXIV (1987) 221; (b) Rangarajan T M & Mathew B, Curr Top Med Chem, 21 (2021) 2695.
- 10 Wagner A, Schellhammer C W & Peterson S, *Angew Chem Int Ed*, 5 (1966) 699.
- 11 Hu S, Zhang S, Hu Y, Tao Q & Wu A, Dyes Pigm, 96 (2013) 509.
- 12 Kumar C K, Trivedi R, Giribabu L, Niveditha S, Bhanuprakash K & Sridhar B, *J Organomet Chem*, 780 (2015) 20.
- 13 Jin M, Liang Y J, Lu R, Chuai X H, Yi Z H, Zhao Y & Zhang H J, Synth Met, 140 (2004) 37.
- 14 Pant G J, Singh P, Rawat B S, Rawat M S M & Joshi G C, Spectrochim Acta A, 78 (2011) 1075.
- 15 Singh P, Negi J S, Singh K, Pant G J, Rawat M S M & Joshi G C, Synth Met, 162 (2012) 1977.
- 16 Bohm H J, Banner D, Bendels S, Kansy M, Kuhn B, Muller K, Sander U O & Stahl M, *ChemBioChem*, 5 (2004) 637.
- 17 Keri R S, Chand K, Budagumpi S, Somappa S B, Patil S A & Nagaraja B M, Eur J Med Chem, 138 (2017) 1002.
- 18 (a) Hampannavar G A, Karpoormath R, Palkar M B, Shaikh M S & Chandrasekaran B, ACS Med Chem Lett, 7 (2016) 686; (b) Pathak V N, Joshi R, Sharma J, Gupta N, & Rao V M, Phosphorus Sulfur Silicon Relat Elem, 184 (2009) 1854.
- (a) Knorr L, Ber Dt Chem Ges, 26 (1893) 100; (b)
 Vounauwers K & Muller, Ber Dt Chem Ges, 41 (1908) 4230.
- (a) Han Z, Yan J, Tang H Q, He Y, Zhu Y, & Ge Y Q, *Tetrahedron Lett*, 58 (2017) 1254; (b) Bhat K I & Jainey P J, *Asian J Pharm Clin Res*, 7(4) (2014) 237.
- 21 Ziani N, Lamara K, Sid A, Willem Q, Dassonneville B & Demonceau A, *Eur J Chem.*, 4 (2013) 176.
- 22 Lam K W, Tham C L, Liew C Y, Syahida A, Rahman M B A, Israf D A &Lajis N H, *Med Chem Res*, 21 (2012) 333.

- 23 Bauer U, Egner B J, Nilsson I & Berghult M, *Tetrahedron Lett*, 41 (2000) 2713.
- 24 Fig. 4 Refer supplementary data.
- (a) Halliwell B & Gutteridge J M, Methods Enzymol, 186 (1990) 1; (b) Halliwell B & Gutteridge J M C, Free Radicals in Biology & Medicine, 3rd ed, (Oxford University Press, Oxford) 1999; (c) Chen S K, Hsu C H, Tsai M L, Chen R H &Drummen G P C, Int J Mol Sci, 14 (2013) 19399.
- 26 Beal M F, Ann Neurol, 38 (1995) 357.
- 27 Khalafalla M M, Abdellatef E, Dafalla H M, Nassrallah A A, Aboul-Enein K M, Lightfoot D A, El-Deeb F E & El-Shemy H A, *African J Biotech*, 9 (2010) 8467.
- 28 Braughler J M, Duncan L A & Chase R L, J biol chem, 261 (1986) P10282.
- 29 Klein S M, Cohen G & Cederbaum A I, *Biochemistry*, 20(21) (1981) 6006.

716